Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
4 Results for "
FASII pathway
" in MedChemExpress (MCE) Product Catalog:
Products (4)
4 Results for "FASII pathway" in MCE Product Catalog:
Synonyms: CG-400549
Target:
Research Areas:
Nilofabicin (CG-400549) is an antibacterial agent that targets FabI; it also inhibits enoyl-acyl carrier protein reductase (ENR) and bacterial fatty acid synthesis (FAS-II) pathway. Nilofabicin shows high selectivity for the genus Staphylococcus and weak activity against most Gram-negative bacteria. Nilofabicin inhibits bacterial fatty acid biosynthesis, blocks phospholipid synthesis, and disrupts the structure of bacterial cell membranes. Nilofabicin exhibits in vivo antibacterial efficacy in a mouse model of systemic Staphylococcus aureus infection. Nilofabicin can be used in studies related to bacterial infections .
Cat. No.: HY-186235
Target:
Research Areas:
3-Hydroxydecanoyl-NAC is a substrate mimetic of the bacterial fatty acid biosynthetic pathway, and exhibits activity against FabA and FabG of Pseudomonas aeruginosa. 3-Hydroxydecanoyl-NAC acts as a stable mimetic of acyl carrier protein-linked fatty acids, which are key intermediates in the bacterial FASII pathway. 3-Hydroxydecanoyl-NAC serves as a substrate for Pseudomonas aeruginosa FabA, enabling the measurement of the dehydration activity of this enzyme .
Cat. No.: HY-187335
Target:
Research Areas:
HadAB/InhA=IN-1 is a dual inhibitor of Mycobacterium tuberculosis InhA and HadAB with an InhA IC50 of 0.81 μM. HadAB/InhA=IN-1 inhibits InhA enzymatic activity in the FAS-II pathway of mycolic acid biosynthesis. HadAB/InhA=IN-1 undergoes EthA-mediated activation to covalently bind HadA and inhibit HadAB dehydratase function in the same FAS-II pathway. HadAB/InhA=IN-1 reduces mycolic acid-containing lipid and mycolic acid production, and accumulates standard fatty acids in Mycobacterium tuberculosis. HadAB/InhA=IN-1 exhibits antimycobacterial activity against drug-susceptible, ethA-deficient, and multi-drug-resistant Mycobacterium tuberculosis isolates. HadAB/InhA=IN-1 shows cytotoxic effects against human cancer and immortalized normal lung fibroblast cells. HadAB/InhA=IN-1 can be used for the research of tuberculosis .
Cat. No.: HY-187941
CAS No.: 2293983-99-8
JSF-3285 is an orally active KasA inhibitor of Mycobacterium tuberculosis (Kd = 70.7 nM). JSF-3285 inhibits KasA in the FAS-II mycolic acid biosynthesis pathway and is active against both drug-susceptible and multidrug-resistant Mycobacterium tuberculosis. JSF-3285 exhibits bactericidal efficacy in acute and chronic mouse models of tuberculosis infection. JSF-3285 significantly enhances the bactericidal and sterilizing efficacy of the Bedaquiline (HY-14881)-Pretomanid (HY-10844) combination regimen in a mouse relapse model of infection. JSF-3285 can be used for research related to tuberculosis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
